40 studies found for:    melanoma | Open Studies | interleukin-2
Show Display Options
RSS Create an RSS feed from your search for:
melanoma | Open Studies | interleukin-2
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting "Re-Stimulated" Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy in Patients With Melanoma
Condition: Metastatic, Stage III or Stage IV, Melanoma
Interventions: Biological: Re-stimulated tumor-infiltrating lymphocytes (TILs);   Biological: Interleukin-2
2 Recruiting Interleukin-2 in Metastatic Melanoma
Condition: Melanoma Metastatic
Intervention: Drug: Interleukin-2
3 Recruiting HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: High Dose Interleukin-2;   Drug: Ipilimumab
4 Recruiting Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab Therapy
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Procedure: scintigraphy;   Other: laboratory biomarker analysis;   Biological: technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2
5 Recruiting A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 in Pretreated Patients With Stage IV Melanoma
Condition: Malignant Melanoma
Interventions: Drug: Interleukin-2;   Drug: Ipilimumab
6 Recruiting Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: IL-2;   Drug: Interferon Alpha-2b
7 Not yet recruiting Tumor Infiltrating Lymphocytes (TIL) Transduced With TGFbDNRII
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Biological: T-Cells;   Drug: Interleukin-2 (IL-2);   Behavioral: Questionnaires
8 Not yet recruiting TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment
Condition: Metastatic Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Genetic: Tumour Infiltrating Lymphocytes;   Drug: Interleukin-2
9 Recruiting Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: Cyclophosphamide and Interleukin 2
10 Not yet recruiting Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
Condition: Metastatic, Stage III or Stage IV, Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Tumor-Infiltrating Lymphocytes;   Biological: Low-Dose Interleukin
11 Recruiting Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
Condition: Metastatic Melanoma
Interventions: Other: Radiation therapy and high-dose IL-2;   Drug: High-dose IL-2
12 Recruiting T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T cells;   Biological: Interleukin-2;   Biological: Dendritic cell vaccine
13 Recruiting T-cell Based Immunotherapy for of Melanoma
Condition: Melanoma
Intervention: Biological: cyclophosphamide, fludarabine, T-cells, Interleukin-2
14 Recruiting IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: Ipilimumab;   Drug: Temozolomide;   Drug: Cisplatin;   Drug: Interferon Alfa-2b;   Drug: Interleukin-2
15 Recruiting Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization
Condition: Melanoma
Interventions: Biological: Dendritic Cell Immunization;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T Cells;   Biological: Interleukin-2;   Drug: Mesna
16 Not yet recruiting Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Procedure: CD8+ T Cells;   Drug: Interleukin-2;   Drug: Ipilimumab
17 Not yet recruiting T-Cells Transduced With Either CXCR2 or Nerve Growth Factor Receptor (NGFR)
Condition: Melanoma
Interventions: Drug: Cytoxan;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Procedure: T cell Infusion;   Drug: IL-2;   Other: Questionnaire
18 Recruiting Fosaprepitant for Nausea and Vomiting During High-dose Interleukin-2 (HD IL-2) for Metastatic Melanoma and Renal Cell Carcinoma
Condition: Chemotherapy-induced Nausea and Vomiting
Intervention: Drug: Fosaprepitant
19 Recruiting Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: High Dose Interleukin-2 (IL-2);   Procedure: ACT with TIL Infusion;   Drug: Vemurafenib;   Drug: Lymphodepletion
20 Recruiting Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients
Condition: Metastatic Melanoma
Intervention: Drug: Proleukin and Dacarbazine

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years